DARE

+ Watchlist + Portfolio

Dare Bioscience, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.82
52-Week Range: $0.75 – $3.78
Market Cap: $15.68M
P/E (TTM): —
EPS (TTM): -0.66
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -39.29%
Gross Margin: 37.19%
Operating Margin: -1582.53%
Profit Margin: 0.00%
Current Ratio: 0.99
Debt/Equity: —
Total Debt: $1.02M
Free Cash Flow: $-6.90M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.01M

DARE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$10.00M	$2.81M	$9.78K	$1.03M
Cost of Revenue	—	—	—	$295.80K
Gross Profit	—	—	—	$734.39K
Research & Development	$30.04M	$21.54M	$14.31M	$5.52M
Selling, General & Admin	$11.24M	$12.11M	$9.16M	$8.76M
Operating Expenses	$41.39M	$33.75M	$23.46M	$14.29M
Operating Income	-$31.39M	-$30.94M	-$23.45M	-$13.55M
EBITDA	-$31.36M	-$30.90M	-$23.41M	-$11.92M
Pretax Income	-$30.95M	-$30.16M	-$4.05M	-$13.40M
Net Income	-$30.95M	-$30.16M	-$4.05M	-$13.40M
Diluted EPS	-4.44	-4.15	-0.48	-1.20
Diluted Shares	7.05M	7.28M	8.50M	11.18M

DARE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$34.67M	$10.48M	$15.70M	$24.71M
Receivables	$1.70M	$949.21K	$229.98K	$573.06K
Current Assets	$43.04M	$17.54M	$18.45M	$27.06M
Total Assets	$43.83M	$21.28M	$22.10M	$32.47M
Current Liabilities	$31.62M	$20.48M	$21.61M	$23.69M
Total Debt	$488.74K	$1.40M	$1.30M	$2.66M
Total Liabilities	$32.71M	$26.33M	$28.11M	$29.63M
Retained Earnings	-$141.07M	-$171.24M	-$175.29M	-$188.69M
Shareholders' Equity	$11.11M	-$5.05M	-$6.01M	$2.84M
Working Capital	$11.41M	-$2.94M	-$3.17M	$3.38M

DARE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$18.09M	-$38.86M	$5.47M	-$9.89M
Capital Expenditure	-$63.07K	-$629.43K	-$573.05K	-$385.28K
Free Cash Flow	-$18.15M	-$39.49M	$4.90M	-$10.27M
Depreciation & Amortisation	$24.20K	$38.36K	$42.33K	$1.63M
Stock-Based Compensation	$2.16M	$2.53M	$2.20M	$1.50M
Investing Cash Flow	-$63.07K	-$629.43K	-$573.05K	-$385.28K
Financing Cash Flow	$1.34M	$15.64M	$354.52K	$19.28M
Net Change in Cash	-$16.81M	-$23.85M	$5.26M	$9.01M

DARE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$25.43K	-$21.17K	$2.26K	$1.02M	$152.46K
Cost of Revenue	$0.00	$0.00	$0.00	$295.80K	$242.32K
Gross Profit	$25.43K	-$21.17K	$2.26K	$727.88K	-$89.87K
Research & Development	$2.30M	$1.43M	$1.18M	$622.04K	$660.46K
Selling, General & Admin	$2.31M	$2.38M	$2.50M	$1.58M	$2.25M
Operating Expenses	$4.61M	$3.81M	$3.67M	$2.20M	$2.91M
Operating Income	-$4.58M	-$3.83M	-$3.67M	-$1.47M	-$3.00M
EBITDA	-$4.41M	-$3.39M	-$3.19M	-$936.87K	-$2.44M
Pretax Income	-$4.38M	-$4.02M	-$3.56M	-$1.44M	-$3.00M
Net Income	-$4.38M	-$4.02M	-$3.56M	-$1.44M	-$3.00M
Diluted EPS	-0.50	-0.45	-0.28	—	-0.21
Diluted Shares	8.76M	8.87M	12.76M	—	14.52M

DARE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$10.33M	$5.04M	$23.08M	$24.71M	$18.52M
Receivables	$105.23K	$188.12K	$369.16K	$573.06K	$687.76K
Current Assets	$11.82M	$6.60M	$25.00M	$27.06M	$21.66M
Total Assets	$18.62M	$12.98M	$30.75M	$32.47M	$27.83M
Current Liabilities	$21.19M	$19.22M	$21.22M	$23.69M	$21.12M
Total Debt	$3.57M	$3.03M	$2.93M	$2.66M	$1.61M
Total Liabilities	$28.18M	$25.71M	$27.89M	$29.63M	$27.09M
Retained Earnings	-$179.67M	-$183.68M	-$187.25M	-$188.69M	-$191.69M
Shareholders' Equity	-$9.56M	-$12.73M	$2.86M	$2.84M	$734.45K
Working Capital	-$9.37M	-$12.62M	$3.79M	$3.38M	$540.12K

DARE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$5.47M	-$5.42M	-$442.13K	$1.44M	-$5.52M
Capital Expenditure	-$157.33K	—	-$174.70K	-$206.64K	—
Free Cash Flow	-$5.63M	-$5.26M	-$616.84K	$1.24M	-$5.52M
Depreciation & Amortisation	$175.64K	$442.54K	$481.91K	$534.39K	$554.64K
Stock-Based Compensation	$377.36K	$359.02K	$403.03K	$357.16K	$455.06K
Investing Cash Flow	-$157.33K	$153.40K	-$174.70K	-$206.64K	$0.00
Financing Cash Flow	$246.58K	-$43.79K	$18.65M	$424.13K	-$715.47K
Net Change in Cash	-$5.38M	-$5.31M	$18.03M	$1.66M	-$6.24M

Market Snapshot

About

Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative products for women's reproductive health. The company's pipeline includes product candidates for vaginal health, contraception, and fertility. Dare's lead programs address conditions such as bacterial vaginosis and include novel hormone therapies and non-hormonal contraceptive options. Based in San Diego, California, the company advances therapies designed to expand choices for women's health and address unmet medical needs.